Board of Directors
William Schwieterman, MD, is President and Chief Executive Officer (CEO) of Mateon. Dr Schwieterman has assembled a world-class management team and is working to transform the organization into a leading oncology company.
Dr Schwieterman is a rheumatologist and board-certified internist, with more than 15 years of executive, regulatory, and drug development experience in the biopharmaceutical industry. He has been an independent consultant to multiple biotech and pharmaceutical clients where he helped them create their regulatory and clinical development strategies. Before joining Mateon, he was an employee of Perceptive Advisors, LLC, a hedge fund based in New York, New York. Dr Schwieterman was also the Chief Medical Officer of Chelsea Therapeutics, Inc., a publicly traded biopharmaceutical development company, where he led the clinical development team toward the approval of droxidopa (Northera™) for the treatment of nonmotor symptoms associated with Parkinson’s disease and other neurogenerative diseases.
Dr Schwieterman was formerly Chief of the Medicine Branch and Chief of the Immunology and Infectious Disease Branch in the Division of Clinical Trials at the Food and Drug Administration (FDA). In these capacities and others, Dr Schwieterman spent 10 years at the FDA in the Center for Biologics overseeing a wide range of clinical development plans for a large number of different types of molecules. Dr Schwieterman holds a BS and MD from the University of Cincinnati.
Dr Chaplin is Chief Scientific Officer (CSO) of Mateon, bringing more than 30 years of experience in oncology research and drug development.
In addition to Dr Chaplin’s current role as CSO and Head of Research and Development at Mateon, he has also served as President and Chief Executive Officer. He has been a leader in the field of vascular targeting and was the first to discover the vascular disrupting action of CA4P (combretastatin A4-phosphate or fosbretabulin). His original work formed the basis for not only the development of CA4P with Mateon, but also the vascular targeting development programs at AstraZeneca and Aventis.
Prior to his association with Mateon, Dr Chaplin was Vice President, Oncology at Aventis Pharma in Paris. Before the merger of Rhone Poulenc Rorer (RPR) with Hoechst Marion Roussell, Dr Chaplin was Senior Director of Oncology at RPR from 1998 to 1999. From 1992 to 1998, Dr Chaplin led the Cancer Research Campaign’s (CRC) Tumor Microcirculation Group, based at the Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, London. Dr Chaplin also served as Section Head of Cancer Biology at Xenova in the United Kingdom and held a senior staff appointment at the British Columbia Cancer Research Centre. Educated in the United Kingdom, Dr Chaplin has a BSc in chemistry from the University of Essex, a MSc in pharmacology from the University of Southampton, and a PhD in tumor biology from the University of London.
Dr Pedder is currently the Vice President of Corporate Strategy and Business Development of Athenex, Inc., a global specialty oncology pharmaceutical company.
Dr Pedder has led the late stage development and commercial launch of several pharmaceutical products. Dr Pedder’s recent leadership roles included serving as President and CEO of Cellectar Biosciences, Inc., and of Chelsea Therapeutics, Inc. Earlier in his career, Dr Pedder was Vice President of the Oncology Pharmaceutical Business at Hoffman-LaRoche. His other roles at Hoffman-LaRoche included Life Cycle Leader and Global Project Leader of Pegasys/IFN, Head of Hepatitis Franchise, Global Project Leader of Pharmaceutical Development, and Director of Clinical Operations. Before joining the pharmaceutical industry, he was on the faculty of the Department of Pharmacology in the College of Medicine at the University of Saskatchewan, where he obtained his PhD in pharmacology.
Mr. Reynolds currently is a partner with the law firm Wyrick, Robbins, Yates & Ponton LLP in Raleigh, North Carolina, with experience in mergers, acquisitions, capital markets, strategic collaborations, divestitures, and corporate governance.
Mr. Reynolds worked closely with Furiex Pharmaceuticals, Inc. prior to its acquisition by Forest/Actavis, and with Salix Pharmaceuticals prior to its acquisition by Valeant Pharmaceuticals. He has held numerous director and advisory board positions in the biopharmaceutical industry, the legal profession and in public service. Mr. Reynolds is currently a member of the board of directors of the Atlantic Research Group, a privately held contract research organization, and of USA Taekwondo, the national governing body for the sport sanctioned by the U.S. Olympic Committee. He is also a member of the National Association of Corporate Directors, and a member of the state bars of California and North Carolina. Mr. Reynolds received his J.D. from New York University School of Lawand his B.A. from Whitman College.
Dr Sandage is currently President and Chief Executive Officer of Euclises Pharmaceuticals, Inc., General Partner of Cultivation Capital and Adjunct Professor in the Department of Pharmaceutical Sciences, School of Pharmacy, Southern Illinois University Edwardsville.
Dr Sandage previously served as an independent pharmaceutical consultant and as President and Chief Executive Officer of Coronado Biosciences, Inc. Earlier in his career, he held senior positions at Indevus Pharmaceuticals, Inc., DuPont Merck Pharmaceutical Company, DuPont Critical Care and Merrell Dow Pharmaceuticals. Over the course of his career, Dr. Sandage has worked on and/or supervised the approval of 14 approved New Drug Applications (NDAs). He received his Ph.D. in Clinical Pharmacy from Purdue University and his B.S. in Pharmacy from the University of Arkansas.